120 related articles for article (PubMed ID: 19581571)
1. Questionable efficacy for naltrexone in patients with Asp40.
Mattes JA
Arch Gen Psychiatry; 2009 Jul; 66(7):796; author reply 796-7. PubMed ID: 19581571
[No Abstract] [Full Text] [Related]
2. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
3. The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers.
Mitchell JM; Fields HL; White RL; Meadoff TM; Joslyn G; Rowbotham MC
J Clin Psychopharmacol; 2007 Feb; 27(1):112-5. PubMed ID: 17224736
[No Abstract] [Full Text] [Related]
4. Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.
O'Brien CP
Curr Psychiatry Rep; 2008 Oct; 10(5):375-6. PubMed ID: 18803909
[No Abstract] [Full Text] [Related]
5. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
Kim SG; Kim CM; Choi SW; Jae YM; Lee HG; Son BK; Kim JG; Choi YS; Kim HO; Kim SY; Oslin DW
Psychopharmacology (Berl); 2009 Jan; 201(4):611-8. PubMed ID: 18795264
[TBL] [Abstract][Full Text] [Related]
6. Prospects for a genomic approach to the treatment of alcoholism.
O'Brien CP
Arch Gen Psychiatry; 2008 Feb; 65(2):132-3. PubMed ID: 18250250
[No Abstract] [Full Text] [Related]
7. Pharmacogenetics of alcoholism: a clinical neuroscience perspective.
Ray LA; Courtney KE; Bujarski S; Squeglia LM
Pharmacogenomics; 2012 Jan; 13(2):129-32. PubMed ID: 22256863
[No Abstract] [Full Text] [Related]
8. Study suggests gene may predict success of therapies for alcohol dependence.
Kuehn BM
JAMA; 2011 Mar; 305(10):984-5. PubMed ID: 21386072
[No Abstract] [Full Text] [Related]
9. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.
Oroszi G; Anton RF; O'Malley S; Swift R; Pettinati H; Couper D; Yuan Q; Goldman D
Alcohol Clin Exp Res; 2009 Mar; 33(3):383-93. PubMed ID: 19053977
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
11. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Kranzler HR; Armeli S; Covault J; Tennen H
Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
Ray LA; Bujarski S; Chin PF; Miotto K
Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
[TBL] [Abstract][Full Text] [Related]
13. Genes harbor clues to addiction, recovery.
Hampton T
JAMA; 2004 Jul; 292(3):321-2. PubMed ID: 15265836
[No Abstract] [Full Text] [Related]
14. The μ-opioid receptor and treatment response to naltrexone.
Thorsell A
Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
[TBL] [Abstract][Full Text] [Related]
15. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
[TBL] [Abstract][Full Text] [Related]
16. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
17. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.
Ray LA; Chin PF; Miotto K
CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):13-22. PubMed ID: 20201811
[TBL] [Abstract][Full Text] [Related]
18. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
[TBL] [Abstract][Full Text] [Related]
19. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.
Chamorro AJ; Marcos M; Mirón-Canelo JA; Pastor I; González-Sarmiento R; Laso FJ
Addict Biol; 2012 May; 17(3):505-12. PubMed ID: 22515274
[TBL] [Abstract][Full Text] [Related]
20. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
